Trials / Unknown
UnknownNCT04272151
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chongqing Precision Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Detailed description
There are limited options for treatment of relapse/refractory Multiple Myeloma. BCMA is expressed on most Multiple Myeloma cells so it is an ideal target for CAR-T. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting BCMA in patients with relapsed/refractory Multiple Myeloma. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA CAR-T cells | A single infusion of BCMA CAR-T cells will be administered intravenously. |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2023-12-31
- Completion
- 2024-07-01
- First posted
- 2020-02-17
- Last updated
- 2023-04-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04272151. Inclusion in this directory is not an endorsement.